MX2023008896A - Inhibidor triciclico fusionado de la cinasa dependiente de ciclina, y metodo de preparacion del mismo y uso farmaceutico del mismo. - Google Patents

Inhibidor triciclico fusionado de la cinasa dependiente de ciclina, y metodo de preparacion del mismo y uso farmaceutico del mismo.

Info

Publication number
MX2023008896A
MX2023008896A MX2023008896A MX2023008896A MX2023008896A MX 2023008896 A MX2023008896 A MX 2023008896A MX 2023008896 A MX2023008896 A MX 2023008896A MX 2023008896 A MX2023008896 A MX 2023008896A MX 2023008896 A MX2023008896 A MX 2023008896A
Authority
MX
Mexico
Prior art keywords
cyclin
dependent kinase
kinase inhibitor
fused tricyclic
preparation
Prior art date
Application number
MX2023008896A
Other languages
English (en)
Inventor
Chao Zhang
Zhen Zhang
Fang Zhang
Hao Zou
Yunfei Li
Haomiao Liu
Xiaming Pang
Honglong Gong
Original Assignee
Tuojie Biotech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuojie Biotech Shanghai Co Ltd filed Critical Tuojie Biotech Shanghai Co Ltd
Publication of MX2023008896A publication Critical patent/MX2023008896A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona un inhibidor de cinasa dependiente de ciclina tricíclico fusionado, así como un método de preparación del mismo y un uso farmacéutico del mismo. En particular, la estructura del inhibidor de cinasa dependiente de ciclina tricíclico fusionado se muestra en la fórmula I, en donde los sustituyentes se definen en la descripción. El inhibidor tricíclico fusionado de la cinasa dependiente de ciclina se utiliza para prevenir y/o tratar enfermedades relacionadas con la cinasa dependiente de ciclina, en particular cánceres. (ver Fórmula).
MX2023008896A 2021-02-03 2022-01-28 Inhibidor triciclico fusionado de la cinasa dependiente de ciclina, y metodo de preparacion del mismo y uso farmaceutico del mismo. MX2023008896A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202110152320 2021-02-03
CN202110342800 2021-03-30
CN202110485700 2021-04-30
CN202110667137 2021-06-16
PCT/CN2022/074509 WO2022166799A1 (zh) 2021-02-03 2022-01-28 稠三环类细胞周期蛋白-依赖性激酶抑制剂及其制备方法和医药用途

Publications (1)

Publication Number Publication Date
MX2023008896A true MX2023008896A (es) 2023-08-09

Family

ID=82741975

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008896A MX2023008896A (es) 2021-02-03 2022-01-28 Inhibidor triciclico fusionado de la cinasa dependiente de ciclina, y metodo de preparacion del mismo y uso farmaceutico del mismo.

Country Status (10)

Country Link
US (1) US20240140963A1 (es)
EP (1) EP4289848A1 (es)
JP (1) JP2024504452A (es)
KR (1) KR20230142735A (es)
CN (1) CN116583524A (es)
AU (1) AU2022217309A1 (es)
CA (1) CA3206898A1 (es)
MX (1) MX2023008896A (es)
TW (1) TW202231282A (es)
WO (1) WO2022166799A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202406912A (zh) * 2022-08-01 2024-02-16 大陸商江蘇恒瑞醫藥股份有限公司 稠三環類衍生物的晶型及製備方法
WO2024066986A1 (zh) * 2022-09-30 2024-04-04 楚浦创制（武汉）医药科技有限公司 2-氨基嘧啶类化合物及其应用、药用组合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105189481A (zh) * 2013-03-13 2015-12-23 艾伯维公司 吡啶cdk9激酶抑制剂
EA035469B1 (ru) * 2013-03-15 2020-06-22 Инсайт Холдингс Корпорейшн Трициклические гетероциклы как ингибиторы белков бэт
CN105294655B (zh) * 2014-07-26 2019-03-15 广东东阳光药业有限公司 Cdk类小分子抑制剂的化合物及其用途
WO2018019204A1 (zh) * 2016-07-26 2018-02-01 深圳市塔吉瑞生物医药有限公司 用于抑制蛋白酪氨酸激酶活性的氨基嘧啶类化合物
US11053238B2 (en) * 2016-12-22 2021-07-06 Betta Pharmaceuticals Co., Ltd. Benzimidazole derivatives, preparation methods and uses thereof
PE20201202A1 (es) * 2018-04-26 2020-11-11 Pfizer Inhibidores de cinasa dependientes de ciclina
CN113698391B (zh) * 2020-05-21 2023-06-06 上海拓界生物医药科技有限公司 4-氨基嘧啶或2-氨基三嗪类化合物及其制备方法

Also Published As

Publication number Publication date
JP2024504452A (ja) 2024-01-31
CA3206898A1 (en) 2022-08-11
AU2022217309A1 (en) 2023-09-14
CN116583524A (zh) 2023-08-11
US20240140963A1 (en) 2024-05-02
KR20230142735A (ko) 2023-10-11
EP4289848A1 (en) 2023-12-13
WO2022166799A1 (zh) 2022-08-11
TW202231282A (zh) 2022-08-16

Similar Documents

Publication Publication Date Title
MX2023008896A (es) Inhibidor triciclico fusionado de la cinasa dependiente de ciclina, y metodo de preparacion del mismo y uso farmaceutico del mismo.
CL2022000271A1 (es) Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina.
MX2022012780A (es) Inhibidores de homologo de oncogen viral de sarcoma de rata kirsten (kras) triciclicos fusionados.
ZA202004729B (en) Pharmaceutical compounds
JOP20220142A1 (ar) مثبطات kras g12c
MX2022005898A (es) Inhibidores de cinasa dependiente de ciclina 7 (cdk7).
MX2022001940A (es) Compuestos de imidazolil pirimidinilamina como inhibidores de cdk2.
GEP20227433B (en) 2-amino-pyridine or 2-amino-pyrimidine derivatives as cyclin dependent kinase inhibitors
MX2020008559A (es) Compuestos heterocíclicos como inhibidores de la quinasa.
TN2019000107A1 (en) Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
ECSP056246A (es) DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA
MY149430A (en) Polycyclic indazole derivatives that are erk inhibitors
MY148609A (en) Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer
ECSP056194A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
MX2022013051A (es) Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos.
CL2022003045A1 (es) Quimioterápicos de éter macrocíclico heteroaromático solicitudes relacionadas
MX2021010321A (es) Compuestos macrociclicos.
MX2020012347A (es) Inhibidor que contiene derivado triciclico, metodo de preparacion del mismo y aplicacion del mismo.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2019006843A (es) Inhibidor de cdk4/6.
PH12020552210A1 (en) Tricyclic compounds
MX2021009426A (es) Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer.
CL2023001367A1 (es) Inhibidores de btk
PH12021551251A1 (en) Heterocyclic compound
CA3173678A1 (en) Cyclin-dependent kinase inhibiting compounds for the treatment of medical disorders